Karen Guerin was formerly a Senior Scientist at Addgene. She started working with viral vectors as a graduate student. As an Addgenie, she focuses on AAV production and quality control.
It was by serendipity that I got into the field of gene therapy, more specifically AAV-based retinal gene therapy. The year was 2001 and I started a job as a technician in a lab using adeno-associated viral vectors (AAVs) to treat an inherited retinal degenerative disease called ...
Adenoviral vectors (AdV) are attractive vectors for research applications and gene therapy: they can be produced at high titers, can accommodate large transgenes, transduce quiescent and dividing cells, and do not integrate into the host’s genome. The main challenge with using ...
A recent survey of PhDs found that many researchers feel that they lack formal training in a variety of transferable skills. At Addgene we've set out to fill this gap by both highlighting that researchers do learn MANY transferable skills while working in the lab and by offering ...
Updated Jun 1, 2021 by Meghan Rego. Reproducible data are key to science, so scientists are used to repeating experiments to confirm their findings. But no scientist wants to repeat an experiment because of poor reagent quality. To make sure our AAV vectors are of the highest ...
